Objective: To investigate the auxiliary diagnostic value of serum total bile acid (TBA) in clinical testing of liver cirrhosis (LC). Methods: A total of 85 patients with LC and 77 patients with hepatitis who were treated in the Affiliated People's Hospital of Jiangsu University from June 2023 to April 2025 were included as the observation group, and 81 healthy people who underwent physical examination in this hospital during the same period were randomly selected as the control group. LC patients comprise 44 cases in the compensated stage and 41 cases in the decompensated stage. The general information of the respondents was collected, and the serum levels of TBA, Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Prealbumin (PA), Gamma-Glutamyltransferase (GGT), Alkaline Phosphatase (ALP), and Adenosine Deaminase (ADA) were measured for patients in each group. Logistic regression was used to analyze the influencing factors of LC. The receiver operating characteristic (ROC) curve was used to evaluate the auxiliary diagnostic value of serum TBA level for LC. Results: Compared with the control group, the levels of TBA, AST, GGT, ALT, ALP, ADA in the LC group were significantly increased, while the level of PA was significantly decreased (p<0.05). Compared with patients in the compensated stage of LC, those in the decompensated stage exhibited a significantly elevated level of serum TBA and a notably reduced level of serum Prealbumin (PA) (P<0.05), while no significant differences were observed in the levels of other serum indicators. Logistic regression showed that TBA (OR=1.018, 95%CI: 1.002~1.034, P<0.05) was an independent risk factor for LC, while PA (OR=0.984, 95%CI: 0.978~0.989, P<0.01) was an independent protective factor for LC. The area under the receiver operating characteristic (ROC) curve (AUC) of serum TBA level in LC patients was 0.892, the 95% confidence interval (CI) was 0.851 to 0.933, and the corresponding sensitivity and specificity were 88.2% and 76.6%, respectively. The AUC of serum TBA level in patients with decompensated cirrhosis was 0.924, the 95% CI was 0.887-0.961, and the corresponding sensitivity and specificity were 97.6% and 74.1%, respectively. Conclusion: The detection of TBA in serum can be used as an auxiliary examination for patients with liver disease, which can provide a certain value for the diagnosis of LC.
| Published in | American Journal of Laboratory Medicine (Volume 10, Issue 2) |
| DOI | 10.11648/j.ajlm.20251002.11 |
| Page(s) | 32-39 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2025. Published by Science Publishing Group |
Liver Cirrhosis, TBA, Auxiliary Diagnosis, Laboratory Tests
| [1] | Dias ML, Paranhos BA, Goldenberg RCD. Liver scaffolds obtained by decellularization: A transplant perspective in liver bioengineering. J Tissue Eng. 2022; 13: 20417314221105305. |
| [2] | Wang Z, Yao LC, Hu X, et al. Advancements in mesenchymal stem cell therapy for liver cirrhosis: Unveiling origins, treatment mechanisms, and current research frontiers. Tissue Cell. 2023; 84: 102198. |
| [3] | Salajegheh F, Rukerd MRZ, Nakhaie M, et al. Efficacy, immunogenicity, and safety of COVID-19 vaccines in individuals with liver cirrhosis: a rapid review and meta-analysis. Clin Exp Vaccine Res. 2024; 13(2): 83-90. |
| [4] | Jiang C, Liu JQ, Li RH, et al. Clinicopathologic characteristics of liver inflammation and fibrosis in 310 patients with chronic hepatitis B. J Cent South Univ (Med Sci). 2023; 48(5): 698-706. |
| [5] | Li J, Wang FZ, Chen ZD, et al. Research advances in the disease burden of viral hepatitis in China. J Clin Hepatol. 2025; 41(02): 221-227. |
| [6] | Chen YJ, Chen SX, Xu CD, et al. Identification of diagnostic biomarkers for compensatory liver cirrhosis based on gut microbiota and urine metabolomics analyses. Mol Biotechnol. 2024; 66(11): 3164-3181. |
| [7] | Guo XY, Zhong X, Zhang TT, et al. Risk factors for death within 30 days after admission in patients with decompensated liver cirrhosis and acute kidney injury and construction of a nomogram model. J Clin Hepatol. 2024; 40(11): 2221-2228. |
| [8] | Xiang ZX, Ning GQ, Deng HQ, et al. Efficiency of PCT, hs-CRP and IL-4 in diagnosis and assessment of spontaneous bacterial peritonitis in patients with decompensated liver cirrhosis. Chin J Nosocomiol. 2022; 32(15): 2254-2258. |
| [9] | Pietri O, Chicaud M, Andreani T, et al. Unexplained chronically elevated aminotransferases: liver biopsy gives major information with therapeutic implication in one patient out of seven. Digest Dis Sci. 2024; 70(3): 1178-1189. |
| [10] | Wang TZ, Wu JS, Meng FK, et al. Value of instantaneous elastic measurement on non invasive diagnosis of early hepatitis B related liver cirrhosis. J Cap Med Univ. 2017; 38(2): 299-303. |
| [11] | El-Serag HB, Thrift AP, Duong H, et al. Serum levels of total bile acids are associated with an increased risk of HCC in patients with cirrhosis. Hepatol Commun. 2024; 8(11): e0545. |
| [12] | Meadows V, Marakovits C, Ekser B, et al. Loss of apical sodium bile acid transporter alters bile acid circulation and reduces biliary damage in cholangitis. Am J Physiol-Gastr L. 2023; 324(1): G60-G77. |
| [13] | Li LL, Xie RQ, Wang L, et al. Correlation analysis between gut microbiota and biochemical indicators of cirrhosis. J Biol. 2021; 38(6): 82-86. |
| [14] | Ginès P, Krag A, Abraldes JG, et al. Liver cirrhosis. Lancet. 2021; 398(10308): 1359-1376. |
| [15] | Zhang Y, Kui HT, Zhang XD, et al. Changes of liver fibrosis and effects of viral loads on serum levels of GP73, HIF-1α, miR-21 and miR-148b in patients with chronic hepatitis B. Chin J Nosocomiol. 2025; 7: 976-980. |
| [16] | Bo LH, Li JB, Wu SX. Effect of bacterial infection in patients with decompensated hepatitis B cirrhosis. Mod Diagn Treat. 2021; 32(14): 2267-2268. |
| [17] | Mekala S, Dugam P, Das A, et al. Ephrin-Eph receptor tyrosine kinases for potential therapeutics against hepatic pathologies. J Cell Commun Signal. 2023; 17(3): 549-561. |
| [18] | Ding C, Wang ZP, Dou XY, et al. Farnesoid x receptor: from structure to function and its pharmacology in liver fibrosis. Aging Dis. 2024; 15(4): 1508-1536. |
| [19] | Liu HQ, Nguyen HH, Hwang SY, et al. Oxidative mechanisms and cardiovascular abnormalities of cirrhosis and portal hypertension. Int J Mol Sci. 2023; 24(23): 16805. |
| [20] | Uegaki S, Tanaka A, Mori Y, et al. Successful treatment with colestimide for a bout of cholestasis in a Japanese patient with benign recurrent intrahepatic cholestasis caused by ATP8B1 mutation. Internal Med. 2008; 47(7): 599-602. |
| [21] | Li N, Zhao X, A NL, et al. Research progress on the role of bile acids in alcoholic liver disease. J Pract Med. 2024; 40(15): 2187-2193. |
| [22] | Zhang XM, Tian YF. Role of abnormal bile acid metabolism in the development of non-alcoholic fatty liver disease. J Kunming Med Univ. 2023; 44(11): 164-169. |
| [23] | Li JN, Du MH, Li H, et al. Low prealbumin levels were associated with increased frequency of hepatic encephalopathy in hepatitis B virus (HBV)-related decompensated cirrhosis. Med Sci Monit. 2023; 29: e937772. |
| [24] | Zhang H, Yang K, Wang Q, et al. Prealbumin as a predictor of short-term prognosis in patients with HBV related acute-on-chronic liver failure. Infect Drug Resist. 2023; 16: 2611-2623. |
| [25] | Ni YH, Qin DY, Wang L. Changes in serum levels of total bile acid, Golgi protein 73, and cancer antigen 19-9 in patients with cirrhosis and their clinical significance. Chin J Gen Surg. 2024; 33(2): 305-310. |
| [26] | Liu N, Zhou YQ. Significance of bile acid in the progress and treatment of liver cirrhosis. Chin J Hepatol, 2022; 27(3): 376-379. |
| [27] | Tajima K, Miuma S, Miyaaki H, et al. Total bile acids levels as a stratification tool for screening portopulmonary hypertension in patients with decompensated cirrhosis. Hepatol Res. 2024; 54(11): 1049-1059. |
| [28] | Niu AR, Qi TG. Diagnostic significance of serum type IV collagen (IVC) combined with aspartate aminotransferase (AST) alanine aminotransferase (ALT) ratio in liver fibrosis. Ann Transl Med. 2022; 10(24): 1310. |
| [29] | Kim S, Lee Y, Bang SM, et al. Early normalization of alanine aminotransferase during antiviral therapy reduces risk of hepatocellular carcinoma in HBV patients. J Clin Med. 2021; 10(9): 1840. |
| [30] | Bouayad A, Laamiri FZ, Elmoumou L, et al. Prevalence of liver fibrosis and cirrhosis in 699 Moroccan patients with chronic hepatitis C. Pan Afr Med J. 2021; 39: 32. |
| [31] | Miao X, Wu GC, An X, et al. Serum fibroblast growth factor 19 as a biomarker in hepatitis B virus-related liver disease. Hepat Mon. 2022; 22(1): e130652. |
| [32] | Yang S, Liu C, Ji XW, et al. The role of gold nanorods in detecting circulating microRNAs as biomarkers in liver diseases. J Biomed Nanotechnol. 2023; 19(10): 1721-1729. |
| [33] | Jeong JY, Cho YS, Sohn JH. Role of two-dimensional shear wave elastography in chronic liver diseases: A narrative review. World J Gastroenterol. 2018; 24(34): 3849-3860. |
| [34] | Xin LL, Wen Z. Assessment of esophageal varices by 2D-SWE technology, FIB-4 and serum VEGF level in patients with hepatitis B-induced liver cirrhosis. J Prac Hepatol. 2024; 27(5): 737-740. |
| [35] | Zhang YY, Wang LJ, Xu YF, et al. Evaluation of APRI combined with FIB-4 index for diagnosing liver cirrhosis in patients with chronic hepatitis B. J Xuzhou Med Univ. 2024; 44(4): 296-301. |
| [36] | Li F, Guo S, Cao XQ. Correlation analysis of intestinal flora imbalance with serum TBA and IL-17 expression in patients with acute purulent cholangitis. J Pathogen Biol. 2023; 18(2): 220-223. |
APA Style
Sun, C., Zhu, Q. (2025). The Auxiliary Diagnostic Value of Serum Total Bile Acids in Liver Cirrhosis at Clinical Test. American Journal of Laboratory Medicine, 10(2), 32-39. https://doi.org/10.11648/j.ajlm.20251002.11
ACS Style
Sun, C.; Zhu, Q. The Auxiliary Diagnostic Value of Serum Total Bile Acids in Liver Cirrhosis at Clinical Test. Am. J. Lab. Med. 2025, 10(2), 32-39. doi: 10.11648/j.ajlm.20251002.11
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ajlm.20251002.11,
author = {Changxiu Sun and Qi Zhu},
title = {The Auxiliary Diagnostic Value of Serum Total Bile Acids in Liver Cirrhosis at Clinical Test
},
journal = {American Journal of Laboratory Medicine},
volume = {10},
number = {2},
pages = {32-39},
doi = {10.11648/j.ajlm.20251002.11},
url = {https://doi.org/10.11648/j.ajlm.20251002.11},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajlm.20251002.11},
abstract = {Objective: To investigate the auxiliary diagnostic value of serum total bile acid (TBA) in clinical testing of liver cirrhosis (LC). Methods: A total of 85 patients with LC and 77 patients with hepatitis who were treated in the Affiliated People's Hospital of Jiangsu University from June 2023 to April 2025 were included as the observation group, and 81 healthy people who underwent physical examination in this hospital during the same period were randomly selected as the control group. LC patients comprise 44 cases in the compensated stage and 41 cases in the decompensated stage. The general information of the respondents was collected, and the serum levels of TBA, Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Prealbumin (PA), Gamma-Glutamyltransferase (GGT), Alkaline Phosphatase (ALP), and Adenosine Deaminase (ADA) were measured for patients in each group. Logistic regression was used to analyze the influencing factors of LC. The receiver operating characteristic (ROC) curve was used to evaluate the auxiliary diagnostic value of serum TBA level for LC. Results: Compared with the control group, the levels of TBA, AST, GGT, ALT, ALP, ADA in the LC group were significantly increased, while the level of PA was significantly decreased (pOR=1.018, 95%CI: 1.002~1.034, POR=0.984, 95%CI: 0.978~0.989, PConclusion: The detection of TBA in serum can be used as an auxiliary examination for patients with liver disease, which can provide a certain value for the diagnosis of LC.
},
year = {2025}
}
TY - JOUR T1 - The Auxiliary Diagnostic Value of Serum Total Bile Acids in Liver Cirrhosis at Clinical Test AU - Changxiu Sun AU - Qi Zhu Y1 - 2025/06/16 PY - 2025 N1 - https://doi.org/10.11648/j.ajlm.20251002.11 DO - 10.11648/j.ajlm.20251002.11 T2 - American Journal of Laboratory Medicine JF - American Journal of Laboratory Medicine JO - American Journal of Laboratory Medicine SP - 32 EP - 39 PB - Science Publishing Group SN - 2575-386X UR - https://doi.org/10.11648/j.ajlm.20251002.11 AB - Objective: To investigate the auxiliary diagnostic value of serum total bile acid (TBA) in clinical testing of liver cirrhosis (LC). Methods: A total of 85 patients with LC and 77 patients with hepatitis who were treated in the Affiliated People's Hospital of Jiangsu University from June 2023 to April 2025 were included as the observation group, and 81 healthy people who underwent physical examination in this hospital during the same period were randomly selected as the control group. LC patients comprise 44 cases in the compensated stage and 41 cases in the decompensated stage. The general information of the respondents was collected, and the serum levels of TBA, Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Prealbumin (PA), Gamma-Glutamyltransferase (GGT), Alkaline Phosphatase (ALP), and Adenosine Deaminase (ADA) were measured for patients in each group. Logistic regression was used to analyze the influencing factors of LC. The receiver operating characteristic (ROC) curve was used to evaluate the auxiliary diagnostic value of serum TBA level for LC. Results: Compared with the control group, the levels of TBA, AST, GGT, ALT, ALP, ADA in the LC group were significantly increased, while the level of PA was significantly decreased (pOR=1.018, 95%CI: 1.002~1.034, POR=0.984, 95%CI: 0.978~0.989, PConclusion: The detection of TBA in serum can be used as an auxiliary examination for patients with liver disease, which can provide a certain value for the diagnosis of LC. VL - 10 IS - 2 ER -
Department of Clinical Laboratory, The Affiliated People’s Hospital of Jiangsu University, Zhenjiang, China
Department of Clinical Laboratory, The Affiliated People’s Hospital of Jiangsu University, Zhenjiang, China
